Skip to main content

8 Result(s)

within H. J. Lambers Heerspink Remove this filter

and

  1. Article

    Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. ‘Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes’

    H. J. Lambers Heerspink, E. Johnsson, I. Gause-Nilsson, C. Sjöström in Diabetologia (2015)

    Download PDF (185 KB) View Article

  2. No Access

    Article

    27. Dapagliflozin Reduces Albuminuria on Top of Renin-Angiotensin System Blockade in Hypertensive Diabetic Patients (1176-P)

    Hypertension (HTN) and albuminuria are risk factors for cardiovascular (CV) and renal disease in patients (pts) with T2DM. Glycemic, blood pressure (BP) and albuminuria control are critical to reducing CV and ...

    H.J. Lambers Heerspink, Eva Johnsson… in Nederlands Tijdschrift voor Diabetologie (2015)

  3. No Access

    Article

    Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

    Medical-product development has become increasingly challenging and resource-intensive. In 2004, the Food and Drug Administration (FDA) described critical challenges facing medical-product development by estab...

    Klaus Romero, Vikram Sinha… in Journal of Pharmacokinetics and Pharmacody… (2014)

  4. Article

    A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

    Microalbuminuria is considered the first clinical sign of kidney dysfunction and is associated with a poor renal and cardiovascular prognosis in type 2 diabetes. Detection of patients who are prone to develop ...

    S. S. Roscioni, D. de Zeeuw, M. E. Hellemons, H. Mischak, P. Zürbig… in Diabetologia (2013)

    Download PDF (226 KB) View Article

  5. No Access

    Article

    On- en off-targeteffecten van dipeptidyl peptidase-4-remmers

    Hoewel patiënten met manifeste diabetes mellitus type 2 (DM2) een verhoogd risico hebben op het ontwikkelen van micro- en macrovasculaire complicaties, begint het proces van subklinische schade al in de vooraf...

    dr. D.J. Mulder, H.J. Lambers Heerspink… in Nederlands Tijdschrift voor Diabetologie (2012)

  6. Article

    Open Access

    High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

    S. S. Roscioni, Y. Miao, D. de Zeeuw, H. J. Lambers Heerspink in Diabetologia (2011)

    Download PDF (103 KB) View Article

  7. Article

    Open Access

    Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

    Y. Miao, D. Dobre, H. J. Lambers Heerspink, B. M. Brenner, M. E. Cooper… in Diabetologia (2011)

    Download PDF (47 KB) View Article

  8. Article

    Open Access

    Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

    To assess the effect of an angiotensin receptor blocker (ARB) on serum potassium and the effect of a serum potassium change on renal outcomes in patients with type 2 diabetes and nephropathy.

    Y. Miao, D. Dobre, H. J. Lambers Heerspink, B. M. Brenner, M. E. Cooper… in Diabetologia (2011)

    Download PDF (182 KB) View Article